DL-Cloprostenol sodium
CAS No. 55028-72-3
MF:C22H30ClNaO6
Molecular weight 448.92
EINECS No. 259-439-3
MF:C22H30ClNaO6
Molecular weight 448.92
EINECS No. 259-439-3
API410
Quantity
DL-Cloprostenol Sodiumis a synthetic prostaglandin F2α (PGF2α) analog formulated as a racemic mixture (D- and L-isomers).
This compound is chemically defined as sodium (±)-9α,11α,15-trihydroxy-16-(3-chlorophenoxy)-17,18,19,20-tetranor-prosta-5Z,13E-dien-1-oate,
It is widely recognized for its high potency and specificity in veterinary medicine and reproductive research.
Superior Luteolytic Activity
DL-Cloprostenol Sodium exhibits 200 times greater potency than natural PGF2α in terminating pregnancy in hamsters and 100 times greater potency in rats, achieving rapid luteolysis (corpus luteum regression) without the side effects associated with native prostaglandins.
Synchronization of Estrus
In livestock management, DL-Cloprostenol Sodium is used to synchronize estrus cycles in cattle, sheep, and swine, optimizing breeding programs and improving reproductive efficiency.
In livestock management, DL-Cloprostenol Sodium is used to synchronize estrus cycles in cattle, sheep, and swine, optimizing breeding programs and improving reproductive efficiency.
Research-Grade Purity
Available at >99% purity, DL-Cloprostenol Sodium is ideal for preclinical studies, including investigations into prostaglandin receptor mechanisms, uterine contractility, and embryo implantation.
Available at >99% purity, DL-Cloprostenol Sodium is ideal for preclinical studies, including investigations into prostaglandin receptor mechanisms, uterine contractility, and embryo implantation.
Flexible Formulation Compatibility
The sodium salt formulation ensures solubility in aqueous buffers, facilitating intravenous, intramuscular, or intrauterine administration in experimental or veterinary settings.
The sodium salt formulation ensures solubility in aqueous buffers, facilitating intravenous, intramuscular, or intrauterine administration in experimental or veterinary settings.
